Literature DB >> 9525632

Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.

T R Kreil1, E Maier, S Fraiss, M M Eibl.   

Abstract

Antibody-mediated neutralization of viruses has been extensively studied in vitro, but the precise mechanisms that account for antibody-mediated protection against viral infection in vivo still remain largely uncharacterized. The two points under discussion are antibodies conferring sterilizing immunity by neutralizing the virus inoculum or protection against the development of disease without complete inhibition of virus replication. For tick-borne encephalitis virus (TBEV), a flavivirus, transfer of neutralizing antibodies specific for envelope glycoprotein E protected mice from subsequent TBEV challenge. Nevertheless, short-term, low-level virus replication was detected in these mice. Furthermore, mice that were exposed to replicating but not to inactivated virus while passively protected developed active immunity to TBEV rechallenge. Despite the priming of TBEV-specific cytotoxic T cells, adoptive transfer of serum but not of T cells conferred immunity upon naive recipient mice. These transferred sera were not neutralizing and were predominantly specific for NS1, a nonstructural TBEV protein which is expressed in and on infected cells and which is also secreted from these cells. Results of these experiments showed that despite passive protection by neutralizing antibodies, limited virus replication occurs, indicating protection from disease rather than sterilizing immunity. The protective immunity induced by replicating virus is surprisingly not T-cell mediated but is due to antibodies against a nonstructural virus protein absent from the virion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525632      PMCID: PMC109757     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Studies of variations of glutamic-oxalacetic transaminase in serum in infectious hepatitis.

Authors:  A J SCHNEIDER; J W MOSLEY
Journal:  Pediatrics       Date:  1959-09       Impact factor: 7.124

Review 2.  Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum.

Authors:  J B Robbins; R Schneerson; S C Szu
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

3.  Monoclonal antibodies directed against tick-borne encephalitis virus with neutralizing activity in vivo.

Authors:  M Niedrig; U Klockmann; W Lang; J Roeder; S Burk; S Modrow; G Pauli
Journal:  Acta Virol       Date:  1994-06       Impact factor: 1.162

Review 4.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

5.  Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.

Authors:  M S Green; D Cohen; Y Lerman; M Sjogren; L N Binn; S Zur; R Slepon; G Robin; C Hoke; W Bancroft
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

6.  Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1.

Authors:  D D'Ambrosio; K L Hippen; S A Minskoff; I Mellman; G Pani; K A Siminovitch; J C Cambier
Journal:  Science       Date:  1995-04-14       Impact factor: 47.728

7.  Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes.

Authors:  A L Rothman; I Kurane; C J Lai; M Bray; B Falgout; R Men; F A Ennis
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

8.  Viral infection of macrophages profoundly alters requirements for induction of nitric oxide synthesis.

Authors:  T R Kreil; M M Eibl
Journal:  Virology       Date:  1995-09-10       Impact factor: 3.616

9.  The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.

Authors:  J J Schlesinger; M Foltzer; S Chapman
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

10.  The NS1 protein of tick-borne encephalitis virus forms multimeric species upon secretion from the host cell.

Authors:  A J Crooks; J M Lee; L M Easterbrook; A V Timofeev; J R Stephenson
Journal:  J Gen Virol       Date:  1994-12       Impact factor: 3.891

View more
  18 in total

1.  Mimicking live flavivirus immunization with a noninfectious RNA vaccine.

Authors:  Regina M Kofler; Judith H Aberle; Stephan W Aberle; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

2.  Mechanistic insights into the impairment of memory B cells and antibody production in the elderly.

Authors:  Judith H Aberle; Karin Stiasny; Michael Kundi; Franz X Heinz
Journal:  Age (Dordr)       Date:  2012-01-27

3.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

4.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 5.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

6.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

7.  Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant.

Authors:  Marco Henkel; Oliver Planz; Timo Fischer; Lothar Stitz; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; K Takada; P W Mason
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

9.  Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.

Authors:  Jian Hang Lam; Yen Leong Chua; Pei Xuan Lee; Julia María Martínez Gómez; Eng Eong Ooi; Sylvie Alonso
Journal:  JCI Insight       Date:  2017-12-21

10.  Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.

Authors:  Douglas G Widman; Tomohiro Ishikawa; Luis D Giavedoni; Vida L Hodara; Melissa de la Garza; Jessica A Montalbo; Amelia P Travassos Da Rosa; Robert B Tesh; Jean L Patterson; Ricardo Carrion; Nigel Bourne; Peter W Mason
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.